1. A randomized, evaluator-blinded, parallel group, no treatment controlled, multicentre study to evaluate effectiveness and safety of GP0109 for augmentation and correction of retrusion in the chin region  (Concluded: 2022)
  2. A Prospective, Single blind, Single-center Study Evaluating the Histology and Intradermal Implantation of the Teosyal RHA® Collection of Fillers (Concluded: 2021)
  3. Study Comparing Hyaluronic Acid Effectiveness & Evaluating Cheek Results with Restylane (CHEEKY Study) (Concluded: 2021)
  4. A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety and Efficacy of MT10109L (NivobotulinumtoxinA) for the Treatment of Glabellar Lines With or Without Concurrent Treatment of Lateral Canthal Lines (Concluded: 2021)
  5. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of QM1114-DP for the Treatment of Moderate to Severe Lateral Canthal Lines and Glabellar Lines Alone or in Combination (READY – 3) (Concluded: 2021)
  6. A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Platysma Prominence (Concluded: 2020)
  7. A Phase 2a, Multicenter, Open-Label, Dose-EscalationStudy to Evaluate the Efficacy and Safety of DaxibotulinumtoxinA (DAXI) for Injection for the Treatment of Dynamic Forehead Lines (Frontalis) Following Glabellar Line Injections (Concluded: 2020)